NCT05078931 2025-07-30A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsShanghai Chest HospitalPhase 2 Active not recruiting35 enrolled
NCT06754644 2025-06-10A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCQilu Pharmaceutical Co., Ltd.Phase 3 Recruiting808 enrolled